24 completed, 11 recruiting, 7 terminated, 7 unknown. 22 Phase 3, 21 Phase 2, 7 Not applicable, 4 Phase 1, 4 Phase 4.
Follow Immunoglobulins: new trials by email Literature Review of Immunoglobulins trials Research Report on Immunoglobulins
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Acalabrutinib, Biospecimen Collection, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | City of Hope Medical Center | 35 | 2026-12-19 | 2026-05-12 |
| Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma Rituximab, Tafasitamab, Biospecimen Collection - Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma | Phase 2 | Recruiting | University of Washington | 30 | 2026-10-09 | 2026-10-15 |
| A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Immune globulin (human) 10% solution for intravenous administration - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 | Recruiting | Kedrion S.p.A. | 161 | 2026-10-01 | 2026-09-11 |
| Immunoglobulin Replacement Therapy (IgRT) Versus Antibiotic Prophylaxis (PA) in Patients Treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B Cell Acute Lymphoblastic Leukemia or a B Cell Lymphoma Immunoglobulin, antibiotic prophylaxis - Chimeric Antigen Receptor T-cell Therapy, B Cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 228 | 2026-09-01 | 2026-08-10 |
| Real-world Evaluation of the Effectiveness of Immunoglobulin-Histamine Complex, IHC (Histoglob) in Chronic Urticaria Antihistaminics, H2 blockers, Leukotriene antagonists, Immunoglobulin/Histamine Complex (IHC) Injection - Chronic Urticaria | Completed | Bharat Serums and Vaccines Limited | 660 | 2025-12-31 | 2026-10-02 | |
| Study on Glucocorticoid Combined With Gamma Globulin and Ropristine N01 in Treatment of Initial Severe ITP corticosteroids combined with immunoglobulin and romiplostim - Primary Immune Thrombocytopenia | Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 36 | 2024-11-20 | 2025-01-22 |
| Intravenous Immunoglobulin Replacement Therapy for Persistent COVID-19 in Patients With B-cell Impairment Immunoglobulins - COVID-19 | Phase 2 | Unknown | Jaehoon Ko | 58 | 2024-03-18 | 2024-05-16 |
| Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation Biopsy, Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy - Chronic Graft Versus Host Disease, Hematologic and Lymphocytic Disorder | Phase 1 | Suspended | City of Hope Medical Center | 27 | 2024-02-19 | 2025-11-13 |
| Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 2 | Recruiting | Academic and Community Cancer Research United | 100 | 2024-01-04 | 2024-11-18 |
| Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Acalabrutinib, Biospecimen Collection, Bone Marrow Aspiration - Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | OHSU Knight Cancer Institute | 27 | 2023-10-02 | 2025-11-06 |
| Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment Biospecimen Collection, Computed Tomography, Lenalidomide - Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma | Phase 2 | Recruiting | SWOG Cancer Research Network | 227 | 2023-09-26 | 2025-10-20 |
| Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma Biopsy, Biospecimen Collection, Carboplatin - Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Active not recruiting | David Bond, MD | 37 | 2023-06-29 | 2026-07-20 |
| Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Active not recruiting | City of Hope Medical Center | 26 | 2023-05-18 | 2026-10-01 |
| Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Immunoadsorption, Immunoglobulins - CIDP | Phase 2 | Recruiting | University of Ulm | 20 | 2023-05-01 | 2026-05-01 |
| Observational Study of Subcutaneous Immunoglobulin (Cutaquig) in Patients With Primary and Secondary Immunodeficiency. Cutaquig® - Primary Immune Deficiency Disorder, Secondary Immune Deficiency | Active not recruiting | University of Alberta | 36 | 2023-04-01 | 2026-05-08 | |
| Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia Cyclophosphamide, Doxorubicin, Etoposide - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Phase 2 | Active not recruiting | University of Washington | 32 | 2023-03-27 | 2026-05-11 |
| Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder Biopsy, Biospecimen Collection, Computed Tomography - Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder | Phase 2 | Recruiting | Timothy Voorhees | 28 | 2023-03-23 | 2026-04-14 |
| Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma Bone Marrow Biopsy, Cyclophosphamide, Doxorubicin - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 1 / Phase 2 | Active not recruiting | University of Washington | 33 | 2023-01-26 | 2026-06-22 |
| Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension trimethoprim-sulfamethoxazole (co-trimoxazole), amoxycillin/clavulanic acid and ciprofloxacin, Immunoglobulins - Haematological Malignancy, Hypogammaglobulinemia | Phase 2 / Phase 3 | Recruiting | Monash University | 300 | 2022-11-30 | 2024-04-19 |
| Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study Acalabrutinib, Cyclophosphamide, Doxorubicin Hydrochloride - Diffuse Large B-Cell Lymphoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 62 | 2022-03-03 | 2026-10-06 |
Showing 20 of 60. Sign in to see all of them.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (7) · Rare Diseases (7) · Mental Disorders (6) · Neurologic Manifestations (6) · Acquired Immunodeficiency Syndrome (4) · HIV Infections (4) · Lymphoma, Large B-Cell, Diffuse (4) · COVID-19 (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Primary Immunodeficiency Diseases (3) · Bacterial Infections (2) · Burkitt Lymphoma (2) · Cytomegalovirus Infections (2) · Diabetic Neuropathies (2) · Hematologic Neoplasms (2)
City of Hope Medical Center (3) · Grifols Therapeutics LLC (3) · University of Washington (3) · Assistance Publique - Hôpitaux de Paris (2) · National Center for Research Resources (NCRR) (2) · National Heart, Lung, and Blood Institute (NHLBI) (2) · University of Oxford (2) · Academic and Community Cancer Research United (1) · Ajou University School of Medicine (1) · American National Red Cross (1) · Beijing Tiantan Hospital (1) · Beth Israel Deaconess Medical Center (1) · Bharat Serums and Vaccines Limited (1) · Biopharma Plasma LLC (1) · Brigham and Women's Hospital (1)
United States (27) · Canada (5) · China (4) · United Kingdom (3) · Australia (2) · Denmark (2) · France (2) · Germany (2) · India (2) · Italy (2) · Puerto Rico (2) · Spain (2) · Sweden (2) · Austria (1) · Belgium (1)
Amandeep Salhotra (1) · Andrew J Pollard, FRCPCH, PhD (1) · Anil K Chandraker, MD (1) · Anthony J. Windebank (1) · Benjamin M Heyman (1) · Bruce Ritchie, MD (1) · Chaim Roifman (1) · Christopher Gibbons, MD (1) · David A Bond, MD (1) · Dimitri Psimaras, MD (1) · Dr Saswata Banerjee (1) · ER Stiehm (1) · Fred D Lublin, MD (1) · Henning Andersen, MD,DMSc,PhD (1)
PMID 16220994, PMID 18645164, PMID 22882285, PMID 28881389, PMID 29084869, PMID 29376112, PMID 29635876, PMID 31621458, PMID 32678530, PMID 33031652, PMID 33031764, PMID 33394942, PMID 33545096, PMID 33568350, PMID 33933206, PMID 34000257, PMID 34013969, PMID 34473343, PMID 34658014, PMID 34672950, PMID 34800427, PMID 35151397, PMID 35695334, PMID 35713300, PMID 35867135, PMID 35908569, PMID 35952327, PMID 36522698, PMID 36734509, PMID 37060915, PMID 37162745, PMID 37489818, PMID 37865101, PMID 37945292, PMID 38272046, PMID 38296965, PMID 38453475, PMID 38489186, PMID 38951929, PMID 39250723, PMID 39319495, PMID 40036152, PMID 40383127, PMID 40886716, PMID 42578463
P30CA033572 (3), 2018 (1), P30CA015083 (1), U10CA013539 (1), U10CA098543 (1), U10CA180886 (1), U10CA180888 (1), UG1CA189828 (1)